Cover Image
市場調查報告書

前列腺肥大症:開發中產品分析

Benign Prostatic Hyperplasia - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 232805
出版日期 內容資訊 英文 113 Pages
訂單完成後即時交付
價格
Back to Top
前列腺肥大症:開發中產品分析 Benign Prostatic Hyperplasia - Pipeline Review, H1 2018
出版日期: 2018年05月16日 內容資訊: 英文 113 Pages
簡介

前列腺是包圍男性尿道的腺體,功能主要是分泌前列腺液(精液的部分成分),前列腺肥大症(BPH)便是該腺體的非癌性肥大疾病,症狀有尿勢低、排尿後滴尿、排尿疼痛、夜間頻尿、腹壓排尿等。BPH的治療有手術和投藥等。

本報告涵括全球前列腺肥大症治療藥的開發平台,提供目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等資訊,為您概述為以下內容。

簡介

  • 調查範圍

前列腺肥大症概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

前列腺肥大症的治療藥開發企土業

  • Addex Therapeutics Ltd
  • AndroScience Corp
  • Aphios Corp
  • BCWorld Pharm Co Ltd
  • Biolab Farmaceutica Ltda
  • Chong Kun Dang Pharmaceutical Corp
  • Curadis GmbH
  • Dongkook Pharmaceutical Co Ltd
  • GL Pharm Tech Corp
  • Hanmi Pharmaceuticals Co Ltd
  • Health Ever Bio-Tech Co Ltd
  • Jeil Pharmaceutical Co Ltd
  • 科研製藥
  • MEI Pharma Inc
  • Meiji Seika Pharma
  • Mezzion Pharma Co Ltd
  • Monosol Rx LLC
  • Nymox Pharmaceutical Corp
  • Ono Pharmaceutical Co Ltd
  • OPKO Health Inc
  • SK Chemicals Co Ltd
  • SOM Biotech SL
  • Sophiris Bio Inc
  • Vantia Therapeutics
  • XuanZhu Pharma Co Ltd
  • Yungjin Pharm Co Ltd

藥物簡介

前列腺肥大症:暫停中的計劃

前列腺肥大症:開發中止的產品

前列腺肥大症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10428IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H1 2018, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 8, 5, 3, 1, 7, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Benign Prostatic Hyperplasia - Overview
    • Benign Prostatic Hyperplasia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Benign Prostatic Hyperplasia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development
    • AndroScience Corp
    • Aphios Corp
    • Aquestive Therapeutics
    • Astellas Pharma Inc
    • BCWorld Pharm Co Ltd
    • Biolab Farmaceutica Ltda
    • Chong Kun Dang Pharmaceutical Corp
    • Curadis GmbH
    • Dongkook Pharmaceutical Co Ltd
    • GemVax & KAEL Co Ltd
    • Health Ever Bio-Tech Co Ltd
    • Jeil Pharmaceutical Co Ltd
    • Kissei Pharmaceutical Co Ltd
    • MEI Pharma Inc
    • Meiji Seika Pharma Co Ltd
    • Mezzion Pharma Co Ltd
    • Nymox Pharmaceutical Corp
    • Ono Pharmaceutical Co Ltd
    • OPKO Health Inc
    • SK Chemicals Co Ltd
    • Sophiris Bio Inc
    • Sun Pharma Advanced Research Company Ltd
    • XuanZhu Pharma Co Ltd
    • Yuyu Pharma Inc
  • Benign Prostatic Hyperplasia - Drug Profiles
    • (alfuzosin hydrochloride ER + tadalafil) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (dutasteride + tadalafil) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (finasteride + tadalafil) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (solifenacin + tamsulosin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (tadalafil + tamsulosin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASC-JM.X2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AUS-131 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BCWPE-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BL-214 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CR-1447 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fexapotide triflutate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KKM-1202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-1AD3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MCS-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCE-403 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONO-7300243 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONO-8430506 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OPK-88004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-0131632 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • silodosin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sirolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Sperol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tadalafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • talaporfin sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tamsulosin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tamsulosin hydrochloride DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tamsulosin SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tertomotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • topsalysin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • udenafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XZP-5849 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YY-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Benign Prostatic Hyperplasia - Dormant Projects
  • Benign Prostatic Hyperplasia - Discontinued Products
  • Benign Prostatic Hyperplasia - Product Development Milestones
    • Featured News & Press Releases
      • May 02, 2018: Nymox Announces Fexapotide Drug Symposium at AUA Annual Meeting San Francisco May 20
      • Apr 16, 2018: GemVax & KAEL Announces Positive Phase 2 Data on GV1001 for Prostate Hyperplasia
      • Apr 10, 2018: New Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of Urology
      • Mar 22, 2018: FDA Grants Fee Waiver for Tamsulosin DRS New Drug Application
      • Mar 01, 2018: Symposium and Panel Discussion on Nymox Fexapotide To Be Held at American Urological Association Mid-Atlantic Section Annual Meeting on March 3
      • Feb 05, 2018: Nymox Announces US NDA for Fexapotide for BPH
      • Jan 30, 2018: Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology
      • Nov 27, 2017: OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy
      • Nov 13, 2017: Veru Announces Tamsulosin DRS Bioequivalence Clinical Trial Results
      • Nov 07, 2017: Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana
      • Oct 13, 2017: Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah
      • Oct 10, 2017: Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah October 12
      • Sep 25, 2017: Nymox Announces October 12 Symposium for Company's BPH Drug at American Urological Association Meeting
      • Sep 15, 2017: Mayne Pharma Adds Urorec (silodosin) Capsules to Its Australian Portfolio
      • Sep 14, 2017: Nymox Announces New Symposium for Company's BPH Drug at American Urological Association Meeting October 5
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Benign Prostatic Hyperplasia, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by AndroScience Corp, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by Aphios Corp, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by Aquestive Therapeutics, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by Astellas Pharma Inc, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co Ltd, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by Biolab Farmaceutica Ltda, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by Curadis GmbH, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by GemVax & KAEL Co Ltd, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by Health Ever Bio-Tech Co Ltd, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by MEI Pharma Inc, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co Ltd, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co Ltd, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corp, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by OPKO Health Inc, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co Ltd, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio Inc, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by XuanZhu Pharma Co Ltd, H1 2018
  • Benign Prostatic Hyperplasia - Pipeline by Yuyu Pharma Inc, H1 2018
  • Benign Prostatic Hyperplasia - Dormant Projects, H1 2018
  • Benign Prostatic Hyperplasia - Dormant Projects, H1 2018 (Contd..1), H1 2018
  • Benign Prostatic Hyperplasia - Dormant Projects, H1 2018 (Contd..2), H1 2018
  • Benign Prostatic Hyperplasia - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Benign Prostatic Hyperplasia, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top